Incyte announces KRAS G12D inhibitor trial data presentations at ESMO 2026

By Public Technologies
  • Incyte will present new oncology data at the ESMO Congress in Madrid, October 23-27, 2026.
  • Findings inform ongoing Phase 3 development of its KRAS G12D inhibitor and TGFβR2×PD-1 antibody, according to research chief Pablo J. Cagnoni.
  • Upcoming presentations cover INCB161734 in advanced colorectal and pancreatic cancers, plus INCA33890 combinations in microsatellite-stable colorectal cancer.
  • Another presentation will report preliminary efficacy of INCB123667 with bevacizumab in recurrent epithelial ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261018477134) on October 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.